ArticleFrontiers in tuberculosis2026
Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination.
Article in Frontiers in tuberculosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms Underlying Antimicrobial Resistance in Mycobacteria.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Major scientific advances across the tuberculosis research continuum emerged in 2025, offering new opportunities to accelerate progress toward global elimination. This review synthesizes developments in diagnosis, treatment, prevention, and post-disease care, highlighting innovations that broaden access, strengthen mechanistic insight, and expand the scope of actionable tools. Diagnostic progress included artificial intelligence-enabled chest imaging, noninvasive molecular testing using tongue and stool samples, simple stool-based procedures suitable for decentralized settings, biomarkers that support treatment monitoring, low-complexity nucleic acid tests for extrapulmonary disease, and new point-of-care methods for detecting infection. Culture-free sequencing approaches further improved rapid identification of drug resistance. Therapeutic advances featured shorter all-oral regimens for drug-susceptible and rifampin-resistant disease, along with emerging compounds that target essential microbial pathways. Additional progress in host-directed therapies, vaccines, and nanoparticle-based drug delivery broadened preventive and therapeutic options. Conceptual developments challenged the validity of symptom-based disease categories and supported biologically grounded terminology, while consensus definitions for post-tuberculosis lung disease clarified the substantial long-term respiratory burden among survivors. Despite this momentum, health-system limitations and inequitable access continue to constrain real-world impact. Collectively, the scientific advances of 2025 were substantial and outline a clearer mechanistic and programmatic path toward tuberculosis elimination, but their success will depend on effective implementation and integration into routine care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.